Literature DB >> 23226573

Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling.

Kazuya Machida1, Malik Khenkhar, Peter Nollau.   

Abstract

It has been a decade since the introduction of SH2 profiling, a modular domain-based molecular diagnostics tool. This review covers the original concept of SH2 profiling, different analytical platforms, and their applications, from the detailed analysis of single proteins to broad screening in translational research. Illustrated by practical examples, we discuss the uniqueness and advantages of the approach as well as its limitations and challenges. We provide guidance for basic researchers and oncologists who may consider SH2 profiling in their respective cancer research, especially for those focusing on tyrosine phosphoproteomics. SH2 profiling can serve as an alternative phosphoproteomics tool to dissect aberrant tyrosine kinase pathways responsible for individual malignancies, with the goal of facilitating personalized diagnostics for the treatment of cancer.

Entities:  

Keywords:  SH2 domain; SH2 profiling; cancer; phosphoproteomics; tyrosine phosphorylation

Year:  2012        PMID: 23226573      PMCID: PMC3513784          DOI: 10.1177/1947601912459048

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  50 in total

1.  Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation.

Authors:  Laura C Kelley; Amanda Gatesman Ammer; Karen E Hayes; Karen H Martin; Kazuya Machida; Lin Jia; Bruce J Mayer; Scott A Weed
Journal:  J Cell Sci       Date:  2010-10-27       Impact factor: 5.285

2.  The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.

Authors:  Jae Hyun Bae; Erin Denise Lew; Satoru Yuzawa; Francisco Tomé; Irit Lax; Joseph Schlessinger
Journal:  Cell       Date:  2009-08-07       Impact factor: 41.582

3.  Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.

Authors:  G Sriram; C Reichman; A Tunceroglu; N Kaushal; T Saleh; K Machida; B Mayer; Q Ge; J Li; P Hornbeck; C G Kalodimos; R B Birge
Journal:  Oncogene       Date:  2011-05-23       Impact factor: 9.867

4.  Defining the specificity space of the human SRC homology 2 domain.

Authors:  Haiming Huang; Lei Li; Chenggang Wu; David Schibli; Karen Colwill; Sucan Ma; Chengjun Li; Protiva Roy; Krystina Ho; Zhou Songyang; Tony Pawson; Youhe Gao; Shawn S-C Li
Journal:  Mol Cell Proteomics       Date:  2007-10-22       Impact factor: 5.911

5.  Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle.

Authors:  Yun-Chung Cheung; John Wen-Cheng Chang; Jia-Juan Hsieh; Gigin Lin; Ying-Huang Tsai
Journal:  Lung Cancer       Date:  2009-05-17       Impact factor: 5.705

Review 6.  Kinases as targets in the treatment of solid tumors.

Authors:  Georgios Giamas; Yik L Man; Heidrun Hirner; Joachim Bischof; Klaus Kramer; Kalimullah Khan; Sharmeen S Lavina Ahmed; Justin Stebbing; Uwe Knippschild
Journal:  Cell Signal       Date:  2010-01-21       Impact factor: 4.315

Review 7.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 8.  Profiling the tyrosine phosphorylation state using SH2 domains.

Authors:  Kevin Dierck; Kazuya Machida; Bruce J Mayer; Peter Nollau
Journal:  Methods Mol Biol       Date:  2009

9.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  6 in total

1.  Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma.

Authors:  Michael Fichtner; Elmar Spies; Henning Seismann; Kristoffer Riecken; Niklas Engels; Barbara Gösch; Judith Dierlamm; Helwe Gerull; Peter Nollau; Wolfram Klapper; Martin Dreyling; Mascha Binder; Martin Trepel
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

Review 2.  Strategies for mass spectrometry-based phosphoproteomics using isobaric tagging.

Authors:  Xinyue Liu; Rose Fields; Devin K Schweppe; Joao A Paulo
Journal:  Expert Rev Proteomics       Date:  2021-10-28       Impact factor: 3.940

3.  SH2-PLA: a sensitive in-solution approach for quantification of modular domain binding by proximity ligation and real-time PCR.

Authors:  Christopher M Thompson; Lee R Bloom; Mari Ogiue-Ikeda; Kazuya Machida
Journal:  BMC Biotechnol       Date:  2015-06-26       Impact factor: 2.563

4.  Bromodomains shake the hegemony of pan-acetyl antibodies.

Authors:  Morgane Champleboux; Jérôme Govin
Journal:  Proteomics       Date:  2015-05       Impact factor: 3.984

Review 5.  Recent findings and technological advances in phosphoproteomics for cells and tissues.

Authors:  Louise von Stechow; Chiara Francavilla; Jesper V Olsen
Journal:  Expert Rev Proteomics       Date:  2015       Impact factor: 3.940

6.  The Protein Tyrosine Phosphatase Rptpζ Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice.

Authors:  Christina Baldauf; Anke Jeschke; Vincent Kanbach; Philip Catala-Lehnen; Daniel Baumhoer; Helwe Gerull; Sophia Buhs; Michael Amling; Peter Nollau; Sheila Harroch; Thorsten Schinke
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.